Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06091124 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma

Study acronym: NEOBLAST
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Jan 1, 2026 to Jan 1, 2027
    • Study sites: 1 to 5
    • Study completion date: Dec 31, 2026 to Dec 31, 2027
    v4
  2. Primary completion date: Dec 31, 2024 to Jan 1, 2026v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Nov 1, 2023 to Nov 16, 2023
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
RenJi Hospital
190 trials monitored
See 2 trials at risk
Bladder Cancer
1,055 trials monitored
See 74 trials at risk
The goal of this clinical trial is to learn about the efficacy and safety of neoadjuvant adebrelimab plus etoposide and cisplatin in patients with neuroendocrine bladder carcinoma. The main questions it aims to answer are: * The pathologic complete response rate at radical cystectomy * Safety and tolerability of combination therapy Participants will be treated with a combination therapy of adebrelimab, etoposide, and cisplatin before radical cystectomy, with a maximum of 4 cycles.
Trial Details
NCT Number NCT06091124
Lead Sponsor RenJi Hospital
Conditions
(from sponsor)		 Neuroendocrine Carcinoma of the Bladder, Bladder Cancer
Related terms Urinary Bladder Neoplasms
Enrollment 22 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov